November 18, 2015 9:31am

For acceptance of ADRO’s IND ADU-741 Application by FDA 


 

IND will enable Janssen, ADRO’s license partner, to initiate multi-center P1 trial to evaluate the safety, immunogenicity of intravenous administration of ADU-741 in patients w/ metastatic castration-resistant prostate cancer

 

The Bottom Line: The P1 trial now expected to start by year end. ADRO eligible to receive future development, regulatory,  commercialization milestone payments up to potential total of $346 M, plus royalties on worldwide net sales upon successful debut and commercialization … to the future.

ADRO closed at $28.87 - BUY

 

 

LADD is ADRO’s proprietary platform of live-attenuated double-deleted Listeria monocytogenes strains that have been engineered to induce a potent innate immune response and to express tumor-associated antigens to induce tumor-specific T cell-mediated immunity.